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Abstract
PURPOSE—To determine the safety and preliminary efficacy of selective combination targeted 
therapy for BRAF V600E–mutant metastatic colorectal cancer (mCRC) in the safety lead-in phase 
of the open-label, randomized, three-arm, phase III BEACON Colorectal Cancer trial 
(ClinicalTrials.gov identifier: NCT02928224; European Union Clinical Trials Register identifier: 
EudraCT2015-005805-35).
PATIENTS AND METHODS—Before initiation of the randomized portion of the BEACON 
Colorectal Cancer trial, 30 patients with BRAF V600E–mutant mCRC who had experienced 
treatment failure with one or two prior regimens were to be recruited to a safety lead-in of 
encorafenib 300 mg daily, binimetinib 45 mg twice daily, plus standard weekly cetuximab. The 
primary end point was safety, including the incidence of dose-limiting toxicities. Efficacy end 
points included overall response rate, progression-free survival, and overall survival.
RESULTS—Among the 30 treated patients, dose-limiting toxicities occurred in five patients and 
included serous retinopathy (n = 2), reversible decreased left ventricular ejection fraction (n = 1), 
and cetuximab-related infusion reactions (n = 2). The most common grade 3 or 4 adverse events 
were fatigue (13%), anemia (10%), increased creatine phosphokinase (10%), increased AST 
(10%), and urinary tract infections (10%). In 29 patients with BRAF V600E–mutant tumors (one 
patient had a non-BRAF V600E–mutant tumor and was not included in the efficacy analysis), the 
confirmed overall response rate was 48% (95% CI, 29.4% to 67.5%), median progression-free 
survival was 8.0 months (95% CI, 5.6 to 9.3 months), and median overall survival was 15.3 
months (95% CI, 9.6 months to not reached), with median duration of follow-up of 18.2 months 
(range, 16.6 to 19.8 months).
CONCLUSION—In the safety lead-in, the safety and tolerability of the encorafenib, binimetinib, 
and cetuximab regimen is manageable and acceptable for initiation of the randomized portion of 
the study. The observed efficacy is promising compared with available therapies and, if confirmed 
in the randomized portion of the trial, could establish this regimen as a new standard of care for 
previously treated BRAF V600E–mutant mCRC.
INTRODUCTION
BRAF V600E mutation is found in approximately 8% to 15% of patients with metastatic 
colorectal cancer (mCRC) and is a marker of poor prognosis.1-4 Because BRAF V600E and 
RAS mutations are nearly always mutually exclusive,5 patients with BRAF V600–mutant 
mCRC have typically been treated with standard-of-care regimens for RAS wild-type 
mCRC.6-9 Standard first-line therapy, even with intensified regimens, produces poorer 
results in patients with BRAF V600E–mutant mCRC than in patients with wild-type disease,
10-12 and after standard first-line therapy, subsequent treatment provides limited benefits, 
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with reported overall response rates (ORRs) of less than 10%, median progression-free 
survival (PFS) times of approximately 2 months, and median overall survival (OS) times 
ranging from 4 to 6 months.2,13-19 Immunotherapies such as nivolumab and pembrolizumab 
are active in patients with microsatellite instability–high or mismatch repair–deficient solid 
tumors, including mCRC.20,21 Although the rate of mismatch repair deficiency is higher in 
BRAF V600E–mutant CRC than in BRAF wild-type disease, recent prospective data and a 
pooled analysis of four clinical trials indicated that less than 20% of patients with BRAF 
V600E–mutant mCRC have microsatellite instability–high or mismatch repair–deficient 
tumors, thus limiting this option to a minority of patients.19,22-24
Unlike in other tumor histologies with BRAF V600 mutations such as melanoma and non–
small-cell lung cancer, where BRAF inhibition is clinically highly active,25-36 BRAF 
inhibition in BRAF V600E–mutant mCRC produced only marginal clinical activity.35,37-39 
In vitro studies later demonstrated that in BRAF V600E–mutant colorectal cancer (CRC) 
cells, BRAF inhibition results in rapid feedback activation of epidermal growth factor 
receptor (EGFR), permitting sustained MAPK activation and continued cell proliferation; 
however, combined inhibition of BRAF and EGFR resulted in synergistic inhibition of 
tumor growth in BRAF V600E–mutant CRC xenograft models.40,41 Subsequent clinical 
studies of EGFR-targeted monoclonal antibodies combined with BRAF inhibition using the 
BRAF inhibitors vemurafenib or dabrafenib confirmed that addition of an EGFR-targeted 
therapy can improve the activity of BRAF inhibition in BRAF V600E–mutant CRC.42-44 In 
addition, preclinical studies indicated that profound inhibition of the MAPK pathway and 
greater antitumor activity could be achieved with the addition of a MEK inhibitor to BRAF 
inhibition, and this was also validated clinically.41,45,46 Despite improvements in the activity 
of these regimens, to date, triplet combinations of BRAF inhibition with EGFR-targeted 
therapy and either a MEK inhibitor or irinotecan have demonstrated response rates of 
approximately 20%, in contrast to response rates of 60% to 70% for combined dual 
BRAF/MEK inhibition alone in melanoma and non–small-cell lung cancer.19,34,36,44,47
The combination of encorafenib, a BRAF inhibitor, and binimetinib, a MEK inhibitor, has 
recently been approved in the United States and Europe for the first-line treatment of 
patients with BRAF V600–mutant melanoma.48,49 Results from a recent phase II study in 
patients with BRAF V600E–mutant mCRC who received at least one prior regimen showed 
that the doublet of encorafenib plus cetuximab resulted in a confirmed ORR of 24%, a PFS 
of 4.2 months, and an OS of 9.3 months with a tolerable safety profile.50 Relative to the 
standard of care and to other BRAF, MEK, and EGFR-inhibitor triplet combinations, the 
promising results with the encorafenib and cetuximab doublet supported the initiation of the 
phase III BEACON CRC study (ClinicalTrials.gov identifier: NCT02928224; European 
Union Clinical Trials Register identifier: EudraCT2015-005805-35).
BEACON CRC is an open-label, randomized, three-arm, phase III study evaluating the 
efficacy and safety of encorafenib plus cetuximab with or without binimetinib versus 
investigators’ choice of cetuximab combined with either irinotecan or fluorouracil, folinic 
acid, and irinotecan in patients with BRAF V600E–mutant mCRC whose disease has 
progressed after one or two prior regimens. At the time BEACON CRC was initiated, the 
triplet combination of binimetinib, encorafenib, and cetuximab had not been clinically 
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evaluated. Therefore, a 30-patient safety lead-in (SLI) was conducted to determine the 
safety, tolerability, and preliminary efficacy of the triplet combination at the doses planned 
for the randomized portion of the trial. Here, we describe results of the BEACON CRC SLI. 
At the time of this analysis, the randomized portion of the trial was ongoing.
PATIENTS AND METHODS
Patients were required to be 18 years of age or older with histologically or cytologically 
confirmed mCRC, with the presence of BRAF V600E mutation in tumor tissue. Patients 
could enroll based on local determination of BRAF V600E mutation; however, confirmation 
by a central laboratory was required for all patients within 30 days of starting treatment. 
Patients must have had progression of disease on at least one but no more than two prior 
treatment regimens in the metastatic setting; have had evidence of measurable or evaluable, 
nonmeasurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 
1.1; have had an Eastern Cooperative Oncology Group performance status of 0 or 1; have 
been eligible to receive cetuximab per their local label; and have had adequate bone marrow, 
renal, hepatic, and cardiac function. Patients were excluded if they had previous treatment 
with any RAF or MEK inhibitor, cetuximab, panitumumab, or other EGFR inhibitor or had 
symptomatic brain metastasis or leptomeningeal disease. Additional details regarding 
inclusion and exclusion criteria are provided in the Data Supplement.
The SLI was performed at seven sites in four countries (two in Belgium, one in the 
Netherlands, two in Spain, and two in the United States). The study was approved by the 
ethics committee for each study site. All clinical work was conducted in compliance with 
current Good Clinical Practices as referenced in the International Conference on 
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human 
Use. All patients enrolled in the study provided written, informed consent before their 
participation.
Study Procedures
The first nine patients were enrolled in the SLI on a rolling basis. These patients received 
encorafenib 300 mg every day plus binimetinib 45 mg twice a day plus cetuximab 400 
mg/m2 followed by 250 mg/m2 intravenously weekly in 28-day cycles. The cohort was to be 
expanded to a total of 30 patients in the dose-expansion cohort based on assessments of the 
safety data in the first nine patients by the data monitoring committee.
Outcome Measures
Safety was evaluated by ongoing monitoring of adverse events, clinical laboratory tests, vital 
signs, physical examinations, ophthalmic examinations, dermatologic examinations, ECGs, 
and echocardiography or multigated acquisition scans. Tumors were assessed using 
radiologic imaging (eg, computed tomography, magnetic resonance imaging, x-ray, whole-
body bone scans), with tumor response determined locally by the investigator and by blinded 
independent central review according to RECIST, version 1.1. Tumor assessments were 
performed every 6 weeks for the first 24 weeks, then every 12 weeks until disease 
progression, withdrawal of consent, or initiation of subsequent anticancer therapy.
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Study population.—All patients who received at least one dose of study drug were 
included in the safety analyses (N = 30). For efficacy analyses, all patients with a BRAF 
V600E mutation (confirmed by local assessment, central assessment, or both) who received 
at least one dose of study drug were included.
End points.—The primary end point of the SLI was the assessment of safety and 
tolerability, which included dose-limiting toxicities (DLTs; defined as any adverse event 
[AE] or abnormal laboratory values assessed as unrelated to disease, disease progression, 
intercurrent illness, or concomitant medications or therapies occurring within the first 28 
days of treatment that met criteria that were established before the start of the study; Data 
Supplement); the incidence and severity of AEs and changes in clinical laboratory 
parameters, vital signs, ECGs, echocardiography or multigated acquisition scans, and 
ophthalmic examinations; and the incidence of dose interruptions, dose modifications, and 
discontinuations.
Efficacy end points included confirmed ORR (per RECIST version 1.1), duration of 
response (DOR), PFS (per RECIST version 1.1), time to response, and OS. Radiographic 
assessment of tumor response and progression was determined locally by the investigator. 
Blinded central review of radiographically determined tumor response and progression was 
also conducted retrospectively and reported. Pharmacokinetic end points were also evaluated 
and will be presented elsewhere.
Statistical analysis.—Descriptive statistics were used to summarize pretreatment 
characteristics and to evaluate DLTs, frequency of AEs, and best overall response. PFS was 
defined as the time from first dose of study drug to the earliest documented date of disease 
progression, per RECIST version 1.1, or death from any cause. OS was defined as the time 
from first dose of study drug to death from any cause. The survival status of all patients was 
assessed as of the cutoff date based on ongoing survival follow-up and public records where 
permitted. Data for patients who did not die by the data cutoff date were censored for OS at 
their last contact date. DOR was defined as time from first radiographic evidence of 
response to the earliest documented disease progression or death. Time to response was 
defined as time from first dose of study treatment to first radiographic evidence of response. 
The Kaplan-Meier method was used to estimate PFS and OS rates. This was also used to 
assess DOR.
RESULTS
Thirty patients were enrolled in the SLI of BEACON CRC between November 1, 2016, and 
April 24, 2017; as of September 2, 2018, treatment remained ongoing for six patients (20%; 
Fig 1). A total of 24 patients (80%) discontinued from the study, with the primary reason for 
study discontinuation being disease progression (n = 21; 70%).
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Patient Disposition and Characteristics
Patient demographic and baseline tumor characteristics are listed in Table 1. Patients were 
characteristic of a population of patients with BRAF V600E–mutant mCRC, with 
predominantly right-sided disease and high frequency of nodal and peritoneal metastasis, 
although the liver was the most frequent site of metastasis. One patient had a non-V600 
mutation of BRAF (G466V) and was included in the safety analysis but excluded from the 
efficacy analysis.
Safety
DLTs.—DLTs were reported in five of 30 patients and included two patients with 
cetuximab-related drug hypersensitivity (grade 2 and grade 3; both patients remained in the 
study on binimetinib and encorafenib), two patients with grade 2 serous retinopathy (both 
patients remained in the study after an interruption of binimetinib dosing), and one patient 
with decreased left ventricular ejection fraction (grade 2) that resolved with the interruption 
of binimetinib dosing (the patient continued in the study on a reduced dose of binimetinib).
AEs.—Two patients (6.7%) experienced grade 1 toxicities; seven (23.3%) experienced 
grade 2 toxicities; 16 (53.3%) experienced grade 3 toxicities; and five (16.7%) experienced 
grade 4 toxicities. No grade 5 toxicities were reported. The most frequently reported 
treatment-emergent AEs (any grade) included diarrhea (77%), dermatitis acneiform (67%), 
fatigue (63%), and nausea (63%). The most frequently reported grade 3 or 4 treatment-
emergent AEs included fatigue (13%; all grade 3), anemia (10%; two grade 3 and one grade 
4), increased AST (10%; one grade 3 and two grade 4), increased creatine phosphokinase 
(10%; all grade 3), and urinary tract infections (10%; all grade 3; Tables 2 and 3).
Drug discontinuations as a result of AEs.—A total of six patients (20%) had at least 
one study drug discontinued as a result of AEs. Among these, one patient (3.3%) 
discontinued all three drugs as a result of grade 2 fatigue; two patients (6.7%) discontinued 
binimetinib alone as a result of increased blood creatinine (n = 1) and retinal detachment (n 
= 1); two patients (6.7%) discontinued cetuximab alone as a result of an allergic reaction; 
and one patient (3.3%) discontinued both encorafenib and binimetinib as a result of 
increased blood bilirubin. At the time of the increased blood bilirubin, there was 
radiographic evidence of extrinsic obstruction of the gallbladder. The patient received a dose 
of cetuximab 2 weeks after discontinuation of encorafenib and binimetinib and then 
discontinued study treatment completely 2 weeks later as a result of clinical progression. 
There were five on-treatment deaths (17%), all a result of disease progression.
Efficacy
Efficacy was assessed in the 29 patients with BRAF V600E mutation–containing tumors. 
The median time on study drug was 7.9 months (range, 1.0 to 21.4 months), and median 
follow-up time for survival was 18.2 months (range, 16.6 to 19.8 months).
Overall response.—Confirmed best overall responses are listed in Table 4. The ORR per 
local assessment was 48% (95% CI, 29.4% to 67.5%). Fourteen patients had a confirmed 
response; three patients (10%) had complete responses, and 11 patients (38%) had partial 
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responses. The ORR, as determined by retrospective central assessment, was 41% (95% CI, 
23.5% to 61.1%), with two complete responses (7%) and 10 partial responses (34%). 
Changes in tumor measurements from baseline are presented in Figure 2.
Among the 17 patients treated with one prior therapy, ORRs per local and central assessment 
were 59% (95% CI, 32.9% to 81.6%) and 53% (95% CI, 27.8% to 77.0%), respectively. 
Among the 12 patients treated with two prior therapies, the local ORR was 33% (95% CI, 
9.9% to 65.1%), with corresponding rates from central assessment of 25% (95% CI, 5.5% to 
57.2%).
Time to response.—Per local assessment, 78.6% of responding patients achieved a 
response within 2 months, 92.9% within 4 months, and all patients within 6 months of 
treatment initiation. On the basis of central assessment, 75.0% of responding patients 
achieved response within 2 months, 91.7% within 4 months, and all patients within 12 
months of treatment initiation.
DOR.—Among responders (n = 14), the median DOR per local assessment was 5.5 months 
(95% CI, 4.1 months to not reached [NR]); 85.7% of patients achieved a DOR of 3 months, 
42.9% achieved a DOR of 6 months, and 25.7% achieved a DOR of 15 months. Median 
DOR among the 12 responders confirmed by central assessment was 8.1 months (95% CI, 
2.8 months to NR); 73% of patients achieved a DOR of 6 months or longer (Data 
Supplement).
PFS and OS.—Median PFS was 8.0 months (95% CI, 5.6 to 9.3 months; Fig 3A) per local 
assessment and 5.5 months (95% CI, 4.2 to 9.3 months) per central assessment. Median PFS 
(by local assessment) by number of prior regimens was similar: 8.0 months (95% CI, 5.6 to 
9.7 months) for patients who received one prior regimen compared with 7.7 months (95% 
CI, 4.1 to 10.8 months) for patients who received two prior regimens. The median OS time 
was 15.3 months (95% CI, 9.6 months to NR; Fig 3B), with median duration of follow-up of 
18.2 months (range, 16.6 to 19.8 months). The 12-month OS rate was 62% (95% CI, 42.1% 
to 76.9%).
DISCUSSION
On the basis of the safety and efficacy results of the SLI phase of the BEACON CRC study, 
the randomized phase of the study was initiated and is ongoing. The safety profile of the 
triplet combination regimen of binimetinib, encorafenib, and cetuximab was similar to that 
previously reported for the individual agents and included predominantly GI and skin 
toxicities. Higher grade (grade 3 or 4) skin toxicities were rare and were less common than 
the 12% rate of grade 3 or 4 rash reported for cetuximab monotherapy,48 suggesting that 
BRAF inhibition may ameliorate this cetuximab-related AE. Although the overall rates of 
grade 3 and grade 4 toxicity were 53.3% and 16.7%, respectively, there was no single 
predominant toxicity driving these rates, with only the event of fatigue (13%) reported at a 
rate higher than 10%. The regimen appeared to be well tolerated and the safety profile 
manageable; a few patients (six patients [20%]) required dose discontinuation of at least one 
of the study drugs as a result of an AE and only one patient discontinued treatment with all 
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three agents as a result of a drug-related AE. Patients requiring dose discontinuation 
included two patients who required discontinuation of cetuximab as a result of infusion 
reactions, a rate consistent with prior reports for cetuximab infusion reactions.51 The 
addition of the MEK inhibitor binimetinib did result in some patients experiencing MEK 
inhibitor class–related AEs including serous retinopathy, increased creatine phosphokinase, 
and decreases in left ventricular ejection fraction. Serous retinopathy (also referred to as 
retinal pigment epithelial detachment) is a known MEK inhibitor–associated toxicity and 
was observed as a grade 2 DLT in two patients. It was documented to reverse in all patients 
who underwent repeat ophthalmologic examination; in one patient, ophthalmologic 
examination was not repeated but the patient continued on study treatment without loss of 
visual acuity. Serous retinopathy is most often asymptomatic, and reported rates depend on 
the frequency of monitoring.29 Symptomatic serous retinopathy is generally reversible and 
manageable with dose interruption, with or without subsequent dose reduction.52 Increased 
creatine phosphokinase was also observed (37%) but is rarely associated with significant 
myopathy, and it led to dose modification in only one patient. Clinically significant MEK 
inhibitor–associated left ventricular dysfunction is uncommon and is generally reversible 
with interruption and dose modification. Grade 2 left ventricular dysfunction was reported as 
a DLT in one patient, was reversed with binimetinib interruption, and did not lead to 
treatment discontinuation.
Benchmarked against both prior standards of care for RAS wild-type metastatic CRC as well 
as more recent experience with other BRAF inhibitor combinations, including triplet 
combinations with cetuximab and either irinotecan or the MEK inhibitor trametinib,19,44 the 
efficacy findings from the SLI are promising. The confirmed ORR was 48%, with 43% of 
responses lasting for more than 6 months. The median PFS time was 8 months and median 
OS time was 15.3 months, with a median duration of follow-up of 18.2 months. Results by 
central review were, in general, consistent with local review findings. By comparison, 
expected outcomes for historical second- and third-line standards of care, similar to the 
control arm of the randomized portion of the trial, included an ORR of less than 10%, 
median PFS of 2 to 3 months, and median OS of 4 to 6 months.2,13-19 Similarly, other triplet 
therapy regimens incorporating a BRAF inhibitor and an EGFR-targeted monoclonal 
antibody (dabrafenib, trametinib, and panitumumab and vemurafenib, irinotecan, and 
cetuximab) have shown improved but limited efficacy, with ORRs of 16% to 21%, median 
PFS of approximately 4.2 to 5.6 months, and median OS of 9.1 to 9.6 months.19,39 Although 
the mechanisms underlying the outcomes associated with encorafenib and binimetinib 
combined with cetuximab remain to be fully characterized, preclinical data suggest that 
encorafenib has target binding characteristics that differ from both vemurafenib and 
dabrafenib, with a prolonged target dissociation half-life and higher potency.53 Clinically, 
although never compared head-to-head with other BRAF/MEK inhibitor combinations, in 
the COLUMBUS trial (ClinicalTrials.gov identifier: NCT01909453) in patients with 
advance BRAF V600K or V600E melanoma,29,36 the combination of binimetinib and 
encorafenib produced new benchmarks for efficacy as measured by PFS (median, 14.9 
months; 95% CI, 11.0 to 18.5 months) and OS (median, 33.6 months; 95% CI, 24.4 to 39.2 
months). Vemurafenib monotherapy, the control arm in the COLUMBUS study, performed 
almost identically to its activity in pivotal trials of other BRAF/MEK inhibitor combinations. 
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In addition, the COLUMBUS trial did include a head-to-head comparison of encorafenib 
monotherapy at 300 mg daily and vemurafenib monotherapy and demonstrated improved 
PFS (hazard ratio, 0.68; 95% CI, 0.52 to 0.88) and OS (hazard ratio, 0.76; 95% CI, 0.58 to 
0.98) for encorafenib relative to vemurafenib in patients with BRAF V600E– or BRAF 
V600K–mutated advanced melanoma.36 Thus, the data suggest that the differences between 
encorafenib and other BRAF inhibitors in terms of target binding may underlie the observed 
differences clinically, including efficacy in BRAF V600E–mutated CRC, which in terms of 
the ability to modulate the MAPK pathway is inherently less sensitive to BRAF inhibition 
than melanoma.40,41
The randomized portion of the BEACON CRC study is ongoing, and if results approximate 
those from the SLI, the combination of binimetinib, encorafenib, and cetuximab may 
become a new standard of care for patients with previously treated BRAF V600E–mutated 
CRC. To maximize the potential for benefit to patients, results warrant additional 
investigation of this regimen in the first-line and potentially the adjuvant settings. A trial to 
investigate the regimen in the first-line setting (ANCHOR-CRC [Encorafenib, Binimetinib, 
and Cetuximab in Subjects With Previously Untreated BRAF-Mutant Colorectal Cancer]; 
ClinicalTrials.gov identifier: NCT03693170) was recently initiated.
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Patient disposition. (*) One treated patient had a non-V600 BRAF mutation (BRAF 
G466V). (†) Includes two patients with changes in condition or development of an 
intercurrent illness. (‡) Dose interruption for more than 28 consecutive days. (§) As of the 
data cutoff date of September 2, 2018. AE, adverse event.
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Best percent change from baseline in sum of tumor diameters based on (A) local assessment 
and (B) central assessment. One patient was without postbaseline sum of diameters (not 
presented). Colors represent best response (confirmed) of partial response (PR) or complete 
response (CR). The category other represents stable disease (SD) or not evaluable (NE). 
Patients with CR, defined as the disappearance of all target lesions, could have pathologic 
lymph node metastases present; target or nontarget lymph node metastases must have had 
reduction in short axis to less than 10 mm. The other category includes stable disease or 
patient not evaluable.
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Kaplan-Meier plots of (A) progression-free survival (PFS; local assessment) and (B) overall 
survival (OS). NR, not reached.
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TABLE 1.
Baseline Patient and Tumor Characteristics (safety population)
Characteristic Patients* (N = 30)
BRAF V600E mutation† 29 (97)
Male 13 (43)
Race
 White 29 (97)
 Black or African American 1 (3)
Median age, years (range) 59 (38-77)
ECOG PS of 0 17 (57)
Location of primary tumor
 Left side 9 (30)
 Right side 18 (60)
 Unknown 3 (10)
No. of organs with metastases ≥ 2 22 (73)
Metastatic site locations
 Liver 20 (67)
 Lymph nodes 15 (50)
 Peritoneum 11 (37)
 Lung 9 (30)
 Other 15 (50)
Resection of primary tumor
 Yes 21 (70)
 No 9 (30)
No. of prior systemic therapies‡
 1 18 (60)
 2 12 (40)
Received prior irinotecan 13 (43)
MSI-H§ 1 (3)
Median CEA at baseline, μg/mL (range) 28 (1-3,434)
Abbreviations: CEA, carcinoembryonic antigen; ECOG PS, Eastern Cooperative Oncology Group performance status; MSI-H, microsatellite 
instability high.
*
Values are numbers and percentages, unless otherwise noted.
†
One patient treated had a non–BRAF V600E mutation.
‡
Includes prior systemic therapies in the metastatic setting only.
§
Based on immunohistochemical assessment of MLH1 and MSH6.
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TABLE 2.
Adverse Events, Regardless of Causality, Reported in Five or More Patients (safety population)
Event
No. of Patients (%) With Adverse
Event of Any Grade (N = 30)*
Total patients with any adverse event† 30 (100.0)
Diarrhea 23 (76.7)
Dermatitis acneiform 20 (66.7)
Fatigue 19 (63.3)
Nausea 19 (63.3)
Dry skin 15 (50.0)
Vomiting 15 (50.0)
Anemia 12 (40.0)
Decreased appetite 12 (40.0)
Abdominal pain 11 (36.7)





Blood creatinine increased 8 (26.7)
Skin fissures 8 (26.7)
Vision blurred 8 (26.7)




Palmar-plantar erythrodysesthesia syndrome 6 (20.0)
Rash maculopapular 6 (20.0)
Back pain 5 (16.7)
Dizziness 5 (16.7)
Ejection fraction decreased 5 (16.7)
Edema peripheral 5 (16.7)
Peripheral sensory neuropathy 5 (16.7)
Rash 5 (16.7)
Rash pustular 5 (16.7)
Urinary tract infection 5 (16.7)
NOTE. Grade is based on National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03.
*
Any single patient may have experienced adverse events under multiple terms (ie, not mutually exclusive).
†
Reported using standard Medical Dictionary for Regulatory Activities dictionary coding.
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TABLE 3.
Grade 3 or 4 Adverse Events, Regardless of Causality, Reported in Two or More Patients (safety population)
Preferred Term No. of patients (%) with grade 3 or 4
Event (N = 30)*
Total patients with any grade 3 or 4 adverse event† 21 (70.0)
Fatigue 4 (13.3)
AST increased 3 (10.0)
Urinary tract infection 3 (10.0)
Anemia 3 (10.0)
Blood creatine phosphokinase increased 3 (10.0)




ALT increased 2 (6.7)
Hypokalemia 2 (6.7)
Hypophosphatemia 2 (6.7)
NOTE. Grade is based on National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03.
*
Any single patient may have experienced adverse events under multiple terms (ie, not mutually exclusive).
†
Reported using standard Medical Dictionary for Regulatory Activities dictionary coding.
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TABLE 4.
Best Overall Response to Treatment




 ORR (CR + PR) 14 (48)
  95% CI (%) 29 to 68
 CR 3 (10)
 PR 11 (38)
 SD 13 (45)
 PD 0
 Not evaluable for response 2 (7)
Central assessment
 ORR (CR + PR) 12 (41)
  95% CI (%) 24 to 61
 CR 2 (7)
 PR 10 (34)
 SD 13 (45)
 PD 0
 Not evaluable for response 4 (14)
NOTE. Data in tables represent No. (%) unless otherwise indicated.
Abbreviations: CR, complete response; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease.
*
Patients with BRAF V600E mutations.
†
Confirmed responses per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
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